Metraipolis › archive › dc_6775d774bdb8
Availability, affordability and access to essential medications for asthma and chronic obstructive pulmonary disease in three low- and middle-income country… — Europe PMC PMID:36962898
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/36962898
- DOI
- 10.1371/journal.pgph.0001309
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-09T23:41:40.035Z
- SHA-256 of the archived text
dcfde79d231db8c1c6d44a569db66169f5cb86f10bdfe64e9aec9574c8ae4f75- Stable URL of this page
https://metraipolis.com/documento/dc_6775d774bdb8
How to cite
Availability, affordability and access to essential medications for asthma and chronic obstructive pulmonary disease in three low- and middle-income country… — Europe PMC PMID:36962898 — Europe PMC (en), https://europepmc.org/article/MED/36962898 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_6775d774bdb8 (Metraipolis archive dc_6775d774bdb8, sha256 dcfde79d231db8c1c6d44a569db66169f5cb86f10bdfe64e9aec9574c8ae4f75)
BibTeX
@misc{dc6775d774bdb8,
title = {Availability, affordability and access to essential medications for asthma and chronic obstructive pulmonary disease in three low- and middle-income country… — Europe PMC PMID:36962898},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/36962898},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_6775d774bdb8; sha256 dcfde79d231db8c1c6d44a569db66169f5cb86f10bdfe64e9aec9574c8ae4f75},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36962898. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Introduction: Despite the rising burden of chronic respiratory disease globally, and although many respiratory medications are included in the World Health Organization Essential Medications List (WHO-EML), there is limited information concerning the availability and affordability of treatment drugs for respiratory conditions in low- and middle-income countries (LMICs). Methods: All public and private pharmacies in catchment areas of the Global Excellence in COPD outcomes (GECo) study sites in Bhaktapur, Nepal, Lima, Peru, and Nakaseke, Uganda, were approached in 2017-2019 to assess pricing and availability of medications for the management of asthma and COPD. Results: We surveyed all 63 pharmacies in respective study areas in Nepal (95.2% private), 104 pharmacies in Peru (94.2% private) and 53 pharmacies in Uganda (98.1% private). The availability of any medication for respiratory disease was higher in private (93.3%) compared to public (73.3%) pharmacies. Salbutamol (WHO-EML) monotherapy in any formulation was the most commonly available respiratory medication among the three sites (93.7% Nepal, 86.5% Peru and 79.2% Uganda) while beclomethasone (WHO-EML) was only available in Peru (33.7%) and Nepal (22%). LABA-LAMA combination therapy was only available in Nepal (14.3% of pharmacies surveyed). The monthly treatment cost of respiratory medications was lowest in Nepal according to several cost metrics: the overall monthly cost, the median price ratio comparing medication costs to international reference prices at time of survey in dollars, and in terms of days' wages of the lowest-paid government worker. For the treatment of intermittent asthma, defined as 100 mcg Salbutamol/Albuterol inhaler, days' wages ranged from 0.47 days in Nepal and Peru to 3.33 days in Uganda. Conclusion: The availability and pricing of respiratory medications varied across LMIC settings, with medications for acute care of respiratory diseases being more widely available than those for long-term management. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLOS global public health, 2022 (prima pubblicazione 2022-12-16). Identificativi: PMID 36962898 · PMCID PMC10021856 · DOI 10.1371/journal.pgph.0001309. Pagina: https://europepmc.org/article/MED/36962898 — https://doi.org/10.1371/journal.pgph.0001309. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-09T22:46:55.086Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.